TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
Telix Pharmaceuticals announced the peer-reviewed publication of Phase 1 results from the ProstACT SELECT study for its lead asset TLX591-Tx in the journal Cancers. The data confirm the utility of PSMA-PET imaging for patient selection and reported a median radiographic progression-free survival (rPFS) of 8.8 months with a manageable safety profile.
Key figures
- Drug Name
- TLX591-Tx
- Phase Of Trial
- Phase 1
- Rpfs months
- 8.8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.